Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440796 | 0.75 | HSD17B10 (0.39) | KDM4EALDH1A1LMNATSHR | |
| SCHEMBL1960375 | 0.74 | KDM4E (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL28027211 | 0.71 | CYP1A2 (0.34) | — | |
| SCHEMBL8571661 | 0.70 | ALDH1A1 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25827883 | 0.69 | ALDH1A1 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3258334 | 0.69 | CA2 (0.50) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3589537 | 0.68 | TAAR1 (0.47) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7827864 | 0.68 | CA2 (0.52) | — | |
| SCHEMBL27176755 | 0.67 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3128402 | 0.67 | TAAR1 (0.47) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1980710-B | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS INC | 2013-06-12 | — | — | CN | disclosed |
| EP-1778243-B1 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2010-07-29 | — | — | US | disclosed |
| US-7718647-B2 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| CN-1980710-A | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS INC (US) | 2007-06-13 | — | — | CN | disclosed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | KDM4E 964/4885USP2 2379/4885ALDH1A1 1011/4885 |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KDM4E 1069/4885USP2 1322/4885ALDH1A1 3864/4885 |
| US-20100190772-A1 | Substituted Azepine Derivatives As Serotonin Receptor Modulators | HTR5A, HTR4, HTR2C | KDM4E 692/4885USP2 2555/4885ALDH1A1 789/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | KDM4E 1069/4885USP2 1322/4885ALDH1A1 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.